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Aims: The prognostic impact of heart rate (HR) in acute heart failure (AHF) patients is not well known
especially in atrial fibrillation (AF) patients. The aim of the study was to evaluate the impact of admission
HR, discharge HR, HR difference (admission-discharge) in AHF patients with sinus rhythm (SR) or AF on
long- term outcomes.
Methods: We included 1398 patients consecutively admitted with AHF between October 2013 and
December 2014 from a national multicentre, prospective registry. Logistic regression models were used
to estimate the association between admission HR, discharge HR and HR difference and one- year all-
cause mortality and HF readmission.
Results: The mean age of the study population was 72 ± 12 years. Of these, 594 (42.4%) were female, 655
(77.8%) were hypertensive and 655 (46.8%) had diabetes. Among all included patients, 745 (53.2%) had
sinus rhythm and 653 (46.7%) had atrial fibrillation. Only discharge HR was associated with one year
all-cause mortality (Relative risk (RR) = 1.182, confidence interval (CI) 95% 1.024–1.366, p = 0.022) in
SR. In AF patients discharge HR was associated with one year all cause mortality (RR = 1.276, CI 95%
1.115–1.459, p  0.001). We did not observe a prognostic effect of admission HR or HRD on long-term
outcomes in both groups. This relationship is not dependent on left ventricular ejection fraction.
Conclusions: In AHF patients lower discharge HR, neither the admission nor the difference, is associated
with better long-term outcomes especially in AF patients.
 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction condition requiring urgent evaluation and treatment, typicallyAcute heart failure (AHF) refers to the rapid onset or worsening
of symptoms and/or signs of HF [1]. It is a life-threatening medicalleading to urgent hospital admission [1]. Despite improvements
in the treatment and outcome of chronic heart failure (HF), those
for AHF have remained relatively unchanged for the last 30 years
[2,3]. Much of this lack of progress can be attributed to imperfect
characterization and understanding of the physiopathology of
AHF [4,5].
2 A.B. Rosa et al. / IJC Heart & Vasculature 26 (2020) 100444Elevated resting heart rate (HR) has been associated with
increased mortality in the general population [6] as well as in those
with coronary artery disease [7,8]. Similar findings have been
reported in patients with HF, although most of these studies exam-
ined patients with chronic HF [9,10].
The prognostic impact of HR in AHF is less well studied and also
few studies have included AHF patients with atrial fibrillation (AF)
or had sufficient power to evaluate potential time-dependent dif-
ferences in the relationship between HR and outcomes [11].
A recent large retrospective study suggested that higher HR was
independently associated with higher in-hospital mortality in AHF
patients [12]. Higher HR in AHF patients presenting to the emer-
gency department also predicted higher 7-day mortality [13].
These observations lead to the inclusion of admission HR in risk
scores for the assessment of short-term prognosis in AHF [14,15].
Despite the importance of HR as a predictor of clinical outcomes
for patients with sinus rhythm [16], limited information about the
relationship of HR (or the change in HR) to post-discharge out-
comes is known in patients with AF and AHF [15].
Also whether early HR reduction improves outcomes in patients
hospitalized with AHF is not clear because a recent study sug-
gested the change in HR during hospitalization was a stronger pre-
dictor of the risk of future cardiac events in patients with AHF
compared with other markers, in patients receiving beta-blockers
[17].
The aim of our study was to evaluate the prognostic value of HR
at admission, HR at discharge and heart rate difference (HRD) in
AHF patients with sinus rhythm (SR) and AF on long-term
outcomes.2. Material and methods
2.1. Study population
We included patients from a national multicentre, prospective
registry (REDINSCORII), which includes input from as many as 20
Spanish hospitals of varying complexity. The registry was compiled
consecutively between October 2013 and December 2014 and
included a total of 1831 patients admitted with acute HF. The
REDINSCORII registry did not include any participants from the
previous REDINSCOR I study, which examined patients with
chronic HF recruited during cardiology consultations [18]. The
study complies with the Declaration of Helsinki, ethics committees
at the participating hospitals approved the study, and all patients
gave written informed consent.
Patients in the registry were older than 18 years and were hos-
pitalized in the cardiology unit for at least 24 h; the main reason
for admission was the presentation of symptoms compatible with
AHF, both de novo and decompensated, and a chest X-ray indicat-
ing pulmonary congestion.
Exclusion criteria included ST-elevation acute coronary syn-
drome, an end-stage disease with a life expectancy <1 year, and
any condition likely to preclude follow-up. Patients with missing
baseline electrocardiograms or in paced rhythm were excluded.
HF diagnostic was made according to the 2012 European Society
of Cardiology HF guidelines [1]. The population was divided
according to the rhythm in two groups: sinus rhythm or atrial fib-
rillation. The flowchart of the patients of the study is shown in Sup-
plementary Figure 1.2.2. Study variables
Data collected for each AHF patient include demographics,
medical/surgical history including any history of AF, admission
medications, admission and discharge vital signs, physical exami-nation, the rhythm at the time of admission, serum laboratory
tests, pharmacological and no pharmacologic interventions, in-
hospital outcomes, and discharge information. In addition, blood
samples were obtained for local laboratory analysis and left ven-
tricular ejection fraction (LVEF) was estimated using Simpson’s
method according to current international recommendations
[19]. HF was defined as being ischemic in aetiology if any of the fol-
lowing criteria were satisfied: prior admission because of an acute
coronary event (acute myocardial infarction or unstable angina),
prior surgical or percutaneous myocardial revascularization, the
presence of myocardial infarction on electrocardiogram or
echocardiogram, or significant coronary disease detected by
angiography.
Heart rhythm was electrocardiographically determined. HR was
determined in conformance with the local protocol for obtaining
vital signs. In all patients, heart rate was electrocardiographically
or telemetrically determined. Heart rate difference (HRD) was
defined as the difference between admission HR less discharge HR.
2.3. Follow-up
In addition to clinical follow-up adjusted to the patient’s needs,
vital status and events were gathered by telephone interview at 1,
3, and 6 months, and at 1 year, if there was no in-person visit at
those time points. Patients who died during the hospitalization
index were excluded (Supplementary Fig. 1). The outcomes for this
analysis were all-cause mortality and HF readmission one-year
after discharge.
2.4. Statistical analysis
Quantitative variables are expressed as mean ± SD and qualita-
tive variables are expressed as frequency (percentage). Qualitative
variables were compared using the chi-square test or the Fisher
exact test, and quantitative variables were compared by the Stu-
dent t-test.
Logistic regression models were used to evaluate the relation-
ship between the outcomes (one-year mortality and one-year
heart failure readmission) with HR (at admission, post-discharge
or difference). We fit unadjusted and adjusted models separately
in SR and AF patients. Adjusted models included age, gender, pre-
vious HF, NT-proBNP levels, LVEF, history of diabetes, betablockers
at discharge, ischemic HF, creatinine levels at admission, sodium
levels at admission, haemoglobin levels at admission, body mass
index (BMI) and systolic blood pressure at admission. We studied
the possible nonlinear effect of each predictor on the outcome,
by means of Generalized Additive Regression models (GAM) using
penalized regression splines [20]. Crude and adjusted relative risks
(RR) and 95% confidence intervals (CI) for a 10-unit increment in
HR were calculated. Interactions were also assessed to study the
relationship between post-discharge-HR and mortality (and HF
readmission) according to LVEF groups (lower or higher than 40%).
Single-variable Cox models were used to evaluate association in
both groups (SR and AF) between the all-time risk of death and of
heart failure readmission and post-discharge HR. Taking data cen-
soring into account, the log hazard ratios of the unadjusted Cox
models were used as criterion variables X to construct time-
dependent Receiver Operating Curves (ROCs) [21] via the corre-
sponding sensitivity and specificity functions: for given time t
and criterion threshold c, sensitivity (c, t) = P(X > c|T  t); speci-
ficity(c,t) = P(X  c|T > t), where T is survival time. For each time
t, the area under the time-dependent ROC [AUC(t)] was calculated.
To deal with missing values, we performed a missing data anal-
ysis [22]. After assuming that these values were missing at ran-
dom, multiple imputations by chained equations were used. The
main reasons for missing data were the lack of NT-proBNP levels
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HF (193, 12.7%), and betablockers at discharge (43, 2.8%), or for
other information (<1%).
Statistical analyses and graphics were carried out in R using the
packages ‘‘mgcv”, ‘‘mice”, ‘‘survival”, ‘‘survivalRoc”, ‘‘voxel” and
‘‘ggplot2”. These packages are freely available at http://cran.r-pro-
ject.org. Differences were considered statistically significant at
P < 0.053. Results
3.1. Baseline characteristics
The final cohort of the population included 1398 patients and
their characteristics are summarized in supplementary Table 1.
The mean age of the analyzed study population was 72 ± 12 years.
Of these, 591 (42.4%) were female. The most frequent risk factor
was hypertension, affecting 1081 patients (77.6%); 652 patients
(46.8%) had diabetes. More than half the patients (776; 55.7%)
had a previous HF diagnosis and the mean LVEF was 45 ± 17%.
Among all included patients, 742 (53.3%) had sinus rhythm and
651 (46,7%) had atrial fibrillation.
The two groups differed significantly in sex, diabetes mellitus,
ischemic aetiology, LVEF, body mass index and in admission HR,
discharge HR and HRD. Overall patients with SR were more fre-
quently prescribed angiotensin-converting enzyme inhibitors
(ACEIs), mineralocorticoid receptor antagonists (MRAs), and sta-
tins; patients with AF received more frequently digoxin and cal-
cium channel blockers.
3.2. Sinus rhythm group
There were 745 patients in the SR group. The mean discharge
HR was 72 ± 13 beats per minute (range 40–127 bpm) and the
patients were classified into four groups according to the discharge
HR (Q1 = 40–63 bpm, Q2 = 63–70 bpm, Q3 = 70–80 bpm, Q4 = 80–
127 bpm). Patients with lower HR at discharge (Q1, Q2) had higher
LVEF, higher doses of amiodarone prescription and lower doses of
diuretics compared with patients with higher HR at discharge (Q3,
Q4). Also, patients with lower HR at discharge had lower HR at
admission (78 ± 22 vs 92 ± 18 bpm, p < 0.001) and higher HR differ-
ence (21 ± 22 vs 1 ± 20 bpm, p < 0.001). We did not find differences
in the betablockers or digoxin prescription (Supplementary
Table 2).
3.3. Atrial fibrillation group
There were 653 patients in the AF group. The mean discharge
HR was 74 ± 15 bpm (range 38–140 bpm). The patients were
divided into four groups according to the discharge HR (Q1 = 38–
64 bpm, Q2 = 64–73 bpm, Q3 = 73–84 bpm, Q4 = 84–140 bpm). The
main differences between were found in terms QRS duration
(Q1 = 117 ± 33 vs. Q4 = 102 ± 26 ms, p < 0.001) and HRD difference
(Q1 = 37 ± 32 vs Q4 = 9 ± 24 bpm, p < 0.001). Patients in Q4 were
prescribed more frequently on digoxin and calcium channel block-
ers and less on ACEIs. These results are shown in Supplemenatary
Table 3.
3.4. Long-term follow up
The one-year all cause mortality was 17.2% (153 patients) in the
SR group and 22.20% (145 patients) in the AF group (p = 0.285). The
one-year HF readmission was 32.1% (229 patients) in the SR group
and 31.8% (199 patients) in the AF group (p = 0.910). The baseline
characteristics are described in supplementary Table 4.4. Prognostic effect of admission HR, discharge HR and HRD on
one year outcomes in SR patients.
Crude and adjusted models observed that according to regres-
sion analysis only discharge HR was associated with all cause
one- year mortality (RR = 1.182, CI: 1.024–1.366, p = 0.022)
(Table 1). However it did not have impact on HF readmission
(RR = 1.027, CI: 0.914–1.155, p = ns). It was also found that age,
systolic blood pressure at admission; creatinine, sodium, and NT-
proBNP levels were predictors of one year all cause mortality (Sup-
plementary Table 5).
A prognostic effect of admission HR or HRD on HF readmission
was not found (Table 1). Previous HF was associated with one-year
HF readmission (Supplementary Table 5).
5. Prognostic effect of admission HR, discharge HR and HRD on
one year outcomes in AF patients
In the same analysis we found that in AF patients discharge HR
was associated with all cause one-year mortality (RR = 1.276, CI
1.115–1.459, p  0.001) (Table 2) with no effect on HF readmission
(RR = 0.938, CI 95%, 0.835–1.053, p = ns) (Table 2). In this group of
patients also diabetes mellitus, age, betablockers prescribed at dis-
charge (OR = 0.51, CI 95% 0.320–0.800), creatinine, hemoglobine
and NT-proBNP levels were associated with one year all cause mor-
tality (Supplementary Table 6).
As in SR patients a prognostic effect of admission HR or HRD on
one year all cause mortality or HF readmission (Table 2) was not
found. However, age, haemoglobin and creatinine, levels were pre-
dictors of one year HF readmission in this group of patients (Sup-
plementary Table 6).
6. Relationship with left ventricular ejection fraction
A significant linear relationship was found between discharge-
HR and mortality in both LVEF groups (LVEF < 40%, LVEF > 40%)
The prognostic value is not dependent on LVEF having the highest
predictive value in AF patients (Figure 1). Discharge HR was not
found to be associated with one-year HF readmission neither in
SR nor AF patients.
6.1. Time-dependent prognostic value
We also performed time- dependent AUC (area under curve) to
determine the effect of dischargeHRduring the 12 months after dis-
charge. In both rhythms, the highest AUC is observed during the first
month postdischarge (Figure 2). However during the follow up dis-
charge HR has higher predictive value in AF compared with SR.
7. Discussion
In this analysis of patients with AHF enrolled in the REDIN-
SCORII multicentre Registry, we observed that only discharge HR
is associated with one-year mortality in SR and AF patients but
not admission HR or HR difference. The magnitude of the associa-
tion is greater in AF patients, especially in the first months post dis-
charge. This relationship is not dependent on LVEF. We
demonstrated that there is a linear relationship between discharge
HR and mortality in AHF patients with AF suggesting that the lower
discharge HR the better outcomes. Indeed, we did not observe HR
effect of one- year HF readmission. Our results suggest that in AHF
only discharge HR should be considered as a therapeutic target in
this population. Several measures aimed to optimize HR at hospital
discharge, including guideline recommended medications that
need to be started during hospital stay especially, in AF patients.
Table 1
Prognostic impact of admission HR, discharge HR and HRD on long -term outcomes in sinus rhythm patients.
All cause one year mortality RR, CI 95% P RR, CI 95% p
HR admission 1.005 (0.928–1.089) 0.896 1.064 (0.971–1.165) 0.182
HR discharge 1.155 (1.020–1.307) 0.022 1.182 (1.024–1.366) 0.022
HR difference 0.950 (0.860–1.050) 0.212 0.995 (0.911–1.088) 0.917
One year HF readmission RR, CI 95% p RR, CI 95% p
HR admission 0.927 (0.862–0.997) 0.041 0.970 (0.895–1.050) 0.447
HR discharge 1.028 (0.922–1.146) 0.621 1.027 (0.914–1.155) 0.651
HR difference 0.924 (0.861–0.990) 0.025 0.962 (0.892–1.037) 0.311
CI: confidence interval; HF: heart failure; HR: heart rate; RR: relative risk
*Adjusted by sex, age, ischemic heart failure, previous HF, creatinine levels, haemoglobin levels, sodium levels, body mass index, left ventricular ejection fraction, NT-proBNP
levels, betablockers at discharge, diabetes mellitus, systolic blood pressure at admission.
Table 2
Prognostic impact of admission HR, discharge HR and HRD on long-term outcomes in atrial fibrillation patients.
All cause one year
mortality
RR, CI 95% p RR, CI 95% p
HR admission 0.909 (0.848–0.973) 0.006 1.003 (0.995–1.012) 0.460
HR discharge 1.214 (1.082–1.362) <0.001 1.276 (1.115–1.459) <0.001
HR difference 0.863 (0.806–0.924) <0.001 0.946 (0.874–1.024) 0.169
One year HF readmission RR, CI 95% p RR, CI 95% p
HR admission 0.918 (0.865–0.975) <0.001 0.953 (0.888–1.024) 0.188
HR discharge 0.931 (0.836–1.036) 0.190 0.938 (0.835–1.053) 0.277
HR difference 0.946 (0.896–1.000) 0.0504 0.980 (0.919–1.046) 0.548
CI: confidence interval; HF: heart failure; HR: heart rate; RR: relative risk.
*Adjusted by sex, age, ischemic heart failure, previous HF, creatinine levels, haemoglobin levels, sodium levels, body mass index, left ventricular ejection fraction, NT-proBNP
levels, betablockers at discharge, diabetes mellitus, systolic blood pressure at admission.
Fig. 1. Effect of post-discharge heart rate on one year all cause mortality, cardiovascular mortality and heart failure readmission in sinus rhythm (A) and atrial fibrillation (B)
patients.
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worsened HF patients has been evaluated in a number of studies
summarized in a recent paper published by Oliva et al. [23]; even
though there is a relative paucity of data on the role of HF at dis-
charge after a phase of clinical instability both in patients with SR
or AF. The EVEREST trial examined 1947 patients with SR and left
ventricular systolic dysfunction who had been admitted for AHF,
in the early pre-discharge increases of HR > 70 bpm have been
shown to be an independent predictor of mortality during the earlyfollow-up; and a 5 bpm increment in the first week post-discharge
was associated with an increase of overall mortality [24]; discharge
HR was also associated with higher mortality in the ASCEND-HF
trial, where no significant interaction effect was observed between
HR at discharge and mortality with beta-blocker therapy at dis-
charge [25].
For the first time we described that in real life patients dis-
charge HR is associated with one year all cause mortality in SR
and AF patients. In SR every increase of 10 bpm increases 18%
Fig. 2. The area under the time-dependent ROC [AUC(t)] of discharge Heart rate in
sinus rhythm and atrial fibrillation patients.
A.B. Rosa et al. / IJC Heart & Vasculature 26 (2020) 100444 5the risk of the one-year all cause mortality and in AF every
increase of 10 bpm increases 27% the risk of the one year all cause
mortality.
Our results are similar to the AHA GWTG-HF prospective reg-
istry that has involved 46,000 patients who have been discharged
after a phase of clinical deterioration, and had found a correlation
between HR at discharge and the likelihood of re-hospitalizations
for all-causes [11]. However in this study, only elderly patients
(>65 years) were included, our results are applied to the all AHF
population regardless of age. Similar findings were described in a
study performed in the context of the EFFECT-HF program with a
significant correlation between HR and early mortality, particularly
in the subgroup of patients with HR comprised between 81 and
90 bpm (hazard ratio: 1.59) and higher than 90 bpm (hazard ratio:
1.56) [26].
Current European Society of Cardiology HF guidelines do not
have a clear recommendation for heart rate control in AHF with
AF [1] and ventricular rates <70 bpm are associated with a worse
outcome [27]. We have demonstrated that the lower discharge
HR the better all cause and cardiovascular mortality (Fig. 2) and
maybe the recommendation of HR between 60 and 100 bpm
should be modified. Our data suggest that post-discharge HR can
offer an important contribution in terms of the determination of
prognosis; nevertheless, it remains to be clarified whether early
HR reduction could have a positive impact on clinical events in
AHF patients. Also, we observed that the prognostic value is higher
in the first months post-discharge so it is reasonable to believe that
post-discharge HR could be an important contribution in the prog-
nostic stratifications of patients with a recent episode of worsening
HF.
To our knowledge, only a small single center registry analyzed
the prognostic impact of HR changes during hospital admission
in patients with AHF. Takahama et al described in this single hos-
pital registry of 421 patients that HR reduction (27 bpm during
in-hospital stay) was associated with a significantly lower cardiac
event rate, isolated HR at discharge was not associated with the
prognosis [17]. In our study we did not observe a relationship
between HRD and outcomes between SR or AF patients hospi-
talised for worsening HF; suggesting that only discharge HR should
be considered as a therapeutic target in this population.As previous studies, we found that admission HR did not have
predictive value with long-term events [24,28]. Such discrepancy
could be explained by the fact that at admission HR represents a
marker of the severity of temporary hemodynamic conditions
and may be therefore a predictor of early, as compared to late,
adverse events [23].
We could not observe the effect of HR on one-year HF readmis-
sion. The prognostic impact of HR in early HF readmission has been
described [26], however, the impact of HR in long term HF read-
mission is not well known and unfortunately, our results could
not clarify this question.
We also found a beneficial effect of betablockers in SR and AF
patients. The role of betablockers in SR patients has been well
established [1], however, Mareev et al. [27] questioned the use of
betablockers in AF and HF patients. Our results reinforced the ben-
eficial effect of betablockers in AF patients and they should be pre-
scribed according to guidelines recommendations [1] in order to
achieve the lower discharge HR especially in AF patients where
the benefices of lowering HR are higher than in SR patients.
Several studies have evaluated the prognostic role of HR in
chronic HF with reduced and preserved ejection fraction with
and without AF [22,23,29,30]. In our study, we described that the
effect of postdischarge HR is not dependent of the LVEF in both
SR and AF patients suggesting that lower discharge HR should be
acquired in reduced and preserved LVEF patients.
Although some studies [23] suggested a J-shaped for HR in
chronic HF patients we studied the possible nonlinear effect of dis-
charge HR on the outcome by using penalized regression splines.
However a linear relationship between HR and mortality was
found. We must acknowledge some limitations; the REDINSCORII
registry includes patients admitted to Spanish cardiology services
with decompensated or de novo HF and who were monitored
prospectively for 1 year. Our results are therefore limited to this
patient category, which is underrepresented in the literature
because most registries include outpatients with stable chronic
HF or a mix of acute and chronic HF patients. Also given the obser-
vational nature, unobserved variables may exert a confounding
effect on the results. HR was measured in two time-points: admis-
sion and discharge; so time until HR control was not taken into
consideration. The evaluated treatments are those prescribed at
hospital discharge, and we are therefore also unable to confirm
whether the therapeutic strategy was maintained throughout the
follow-up period, a factor that could influence prognosis. We did
not have information about how many patients who were admit-
ted with atrial fibrillation were cardioverted to sinus rhythm. How-
ever our results showed the impact of HR in a real cohort of
patients with AHF.8. Conclusions
In a cohort of AHF patients, only high discharge HR is associated
with worse outcomes in SR and AF patients. Our study suggests
that HR should be optimized with guideline recommended medi-
cations in the transition from hospital to ambulatory care in the
community especially in AF patients.Funding
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